GLP-1 medicines have reframed obesity as a chronic, treatable disease rather than a behavioural failing. This book reviews semaglutide across obesity, type 2 diabetes, and metabolic fatty liver disease — the evidence, the formulations, and what it means for patients and health systems.
Semaglutide: A New Look at Obesity, Diabetes, Fatty Liver and the Future of Treatment
Medicines acting on the GLP-1 pathway have changed how obesity is understood — from a behavioural issue to a chronic, treatable disease. Prof. Seyed-Moayed Alavian reviews semaglutide across obesity, type 2 diabetes, and metabolic fatty liver disease: what the trials show, how the formulations differ, and what it all means for patients, physicians, and health policymakers.
Publisher
Publication date
February 6, 2026
Print length
335 pages
Language
English
Format
Kindle edition
Subject
GLP-1 therapies, obesity, diabetes, and MASH
Audience
Patients, physicians, and health policymakers
Get the book
Published by Brieflands and available worldwide as a Kindle edition on Amazon. For institutional orders, bulk copies, or translation rights, contact the publisher directly.
About this book
The rise of obesity and metabolic disease across societies has made the case for novel, evidence-based treatment approaches unavoidable. Medications targeting the GLP-1 hormonal pathway are among the most significant therapeutic advances of recent years, enabling more effective weight management and improvement in metabolic disorders — and shifting the framing of obesity from a behavioural problem to a chronic, treatable disease.
The book traces semaglutide's regulatory history, from its approval for long-term weight management in adults with obesity, through the formulations approved for type 2 diabetes, to the oral formulation and, most recently, the approval of injectable semaglutide for adults with metabolic steatohepatitis (MASH) accompanied by moderate to advanced fibrosis.
That last development is examined in detail. Evidence discussed in the book indicates that semaglutide's effect on fatty liver disease extends beyond weight loss: sustained weight reduction, improved insulin resistance, and reduced systemic inflammation each lower liver fat, while phase 3 trial data suggest effects on the structure of the disease itself — resolution of hepatic inflammation and, in a subset of patients, improvement in fibrosis.
The book also covers the localisation of these therapies, including Soyma, an Iranian semaglutide formulation developed to widen access and reduce dependence on imported products. Throughout, the aim is to bridge specialised knowledge and practical understanding so that readers can make informed, realistic decisions.
What the book covers
The GLP-1 pathway
The biological mechanism these drugs act on, explained for a clinical and lay readership alike.
Formulations compared
How the injectable and oral formulations differ, and which indications each carries.
Obesity and weight management
The evidence on sustained weight loss, maintenance, and cardiovascular risk factors.
Metabolic fatty liver disease
Effects on liver fat, inflammation, and fibrosis — and why the MASH data mattered.
Access and affordability
Localised production, including Soyma, and what wider access means for health systems.
For decision-makers
A bridge between specialised evidence and the practical decisions patients and policymakers face.
Important. Semaglutide is a prescription medicine. This book is educational and does not recommend, prescribe, or provide dosing guidance, and regulatory approvals and indications differ between countries. Decisions about starting, changing, or stopping any obesity, diabetes, or liver treatment must be made with a qualified clinician who can weigh your history, other medicines, and possible adverse effects. Never obtain prescription medicines from unregulated sources or compounded copies sold online.